Integra Lifesciences Holdings Corp [NASDAQ: IART] loss -23.46% or -3.62 points to close at $11.81 with a heavy trading volume of 4783248 shares.
It opened the trading session at $15.23, the shares rose to $15.395 and dropped to $11.05, the range by which the price of stock traded the whole day. The daily chart for IART points out that the company has recorded -28.16% loss over the past six months.
If we look at the average trading volume of 1.21M shares, IART reached to a volume of 4783248 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Integra Lifesciences Holdings Corp [IART]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IART shares is $15.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IART stock is a recommendation set at 3.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Argus have made an estimate for Integra Lifesciences Holdings Corp shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 31, 2025. While these analysts kept the previous recommendation, Morgan Stanley dropped their target price from $25 to $20. The new note on the price target was released on December 02, 2024, representing the official price target for Integra Lifesciences Holdings Corp stock. On July 30, 2024, analysts decreased their price target for IART shares from 30 to 23.
The Price to Book ratio for the last quarter was 0.89, with the Price to Cash per share for the same quarter was set at 3.26.
Trading performance analysis for IART stock
Integra Lifesciences Holdings Corp [IART] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -25.63. With this latest performance, IART shares dropped by -19.82% in over the last four-week period, additionally sinking by -28.16% over the last 6 months – not to mention a drop of -47.93% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IART stock in for the last two-week period is set at 31.53, with the RSI for the last a single of trading hit 1.10, and the three-weeks RSI is set at 0.90 for Integra Lifesciences Holdings Corp [IART]. The present Moving Average for the last 50 days of trading for this stock 14.73, while it was recorded at 14.97 for the last single week of trading, and 16.67 for the last 200 days.
Integra Lifesciences Holdings Corp [IART]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Integra Lifesciences Holdings Corp [IART] shares currently have an operating margin of 9.05% and a Gross Margin at 55.71%. Integra Lifesciences Holdings Corp’s Net Margin is presently recorded at -30.87%.
Integra Lifesciences Holdings Corp (IART) Capital Structure & Debt Analysis
According to recent financial data for Integra Lifesciences Holdings Corp. ( IART), the Return on Equity (ROE) stands at -38.92%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -12.93%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Integra Lifesciences Holdings Corp’s Return on Invested Capital (ROIC) is -20.65%, showcasing its effectiveness in deploying capital for earnings.
Integra Lifesciences Holdings Corp (IART) Efficiency & Liquidity Metrics
Based on Integra Lifesciences Holdings Corp’s (IART) latest financial statements, the Debt-to-Equity Ratio is 1.94%, indicating its reliance on debt financing relative to shareholder equity.
Integra Lifesciences Holdings Corp (IART) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Integra Lifesciences Holdings Corp. (IART) effectively leverages its workforce, generating an average of -$113883.08 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.23% and a Quick Ratio of 0.73%, indicating strong ability to cover short-term liabilities.
Integra Lifesciences Holdings Corp [IART]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Integra Lifesciences Holdings Corp posted 0.97/share EPS, while the average EPS was predicted by analysts to be reported at 0.85/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.12. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IART. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Integra Lifesciences Holdings Corp go to 0.93%.
An analysis of Institutional ownership at Integra Lifesciences Holdings Corp [IART]
There are presently around $94.01%, or 109.24%% of IART stock, in the hands of institutional investors. The top three institutional holders of IART stocks are: BLACKROCK INC. with ownership of 11.25 million shares, which is approximately 14.5376%. VANGUARD GROUP INC, holding 7.77 million shares of the stock with an approximate value of $$226.5 million in IART stocks shares; and VANGUARD GROUP INC, currently with $$160.23 million in IART stock with ownership which is approximately 7.1032%.
